Genetic Testing for FLT3, NPM1, and CEBPA Mutations in Acute Myeloid Leukemia
ثبت نشده
چکیده
©2017 Blue Cross and Blue Shield of Louisiana An independent licensee of the Blue Cross and Blue Shield Association No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana. Page 1 of 12 Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.
منابع مشابه
Genetic Testing for FLT3, and NPM1, and CEBPA Mutations in Cytogenetically Normal Acute Myeloid Leukemia
متن کامل
Genetic Testing for FLT3, and NPM1, and CEBPA Mutations in Cytogenetically Normal Acute Myeloid Leukemia
متن کامل
Genetic Testing for FLT3, and NPM1, and CEBPA Mutations in Cytogenetically Normal Acute Myeloid Leukemia
متن کامل
Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
PURPOSE To determine the clinical relevance of mutations in the CCAAT/enhancer binding protein alpha (CEBPA) gene in acute myeloid leukemia (AML) and to examine factors that might modify prognostic impact. PATIENTS AND METHODS The entire CEBPA coding sequence was screened in 1,427 young adult patients with AML, excluding acute promyelocytic leukemia, using denaturing high-performance liquid c...
متن کاملClinical relevance of mutant NPM1 and CEBPA in patients with acute myeloid leukaemia – preliminary report
AIM OF THE STUDY Mutant NPM1 and CEBPA have been reported in patients with acute myeloid leukaemia (AML) and intermediate cytogenetic risk, and they appear to be associated with characteristic demographic and laboratory data, as well as clinical outcome. The objective of the study was to assess the clinical relevance of NPM1 and CEBPA mutations in AML. MATERIAL AND METHODS This retrospective ...
متن کامل